New York, NY -- (ReleaseWire) -- 02/01/2013 -- Growing Stock Report adds Echo Therapeutics, Inc. (NASDAQ:ECTE) and ARCA biopharma, Inc. (NASDAQ:ABIO) to their Nasdaq Biotech and Drug Maker Decliners Watch List.
Echo Therapeutics, Inc. (NASDAQ:ECTE) a company that operates as a transdermal medical device company in the United States is currently down (-29.99%) after the company said its stock offering of 13.3 million shares priced at a 35% discount to Thursday’s closing price. This has prompted Growing Stock Report to add Echo Therapeutics, Inc. (NASDAQ:ECTE) to their Nasdaq's Biotech Decliners Watch List.
Click Here to find out what other Investors are saying about Echo Therapeutics, Inc.
ARCA biopharma, Inc. (NASDAQ:ABIO) a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases is currently down (-24.68%) on news that yesterday, ARCA biopharma, Inc. (NASDAQ:ABIO) entered into a placement agency agreement with Dawson James Securities, Inc. pursuant to which the Placement Agent agreed to use its reasonable best efforts to arrange for the sale of up to 987,820 shares ARCA biopharma, Inc.'s common stock and warrants to purchase up to 395,128 shares of ARCA's common stock in one or more public offerings under the Company's registration. The stock has not reacted favorably to this and is currently trending downward.
Click Here to find out what other Investors are saying about ARCA biopharma, Inc.
GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities.
Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed.
Timing is important when trading Small Caps and Penny Stocks.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.GrowingStockReport.com
Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.
Growing Stock Report